Role of single nucleotide polymorphisms in pharmacogenomics and their association with human diseases

References

• Ahern MJ, Harrison W, Hollingsworth P, et al. (1991). A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Aust N Z J Med 21:844–849
   PubMedGoogle Scholar
• Altshuler D, Hirschhorn JN, Klannemark M, et al. (2000). The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80
   PubMed Web of Science ®Google Scholar
• Aquilante CL, Yarandi HN, Cavallari LH, et al. (2008). Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography. Pharmacogenomics J 8:408–415
   PubMed Web of Science ®Google Scholar
• Arnett DK, Claas SA, Glasser SP. (2006). Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol 44:107–118
   PubMed Web of Science ®Google Scholar
• Barnes PJ. (2006). Drugs for asthma. Br J Pharmacol 147:S297–S303
   PubMed Web of Science ®Google Scholar
• Berkun DL, Rubinow A, Orbach H, et al. (2004). Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63:1227–1231
   PubMed Web of Science ®Google Scholar
• Black AJ, McLeod HL, Capell HA. (1998). Thiopurinemethyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 129:716–718
   PubMed Web of Science ®Google Scholar
• Bozec E, Fassot C, Tropeano AI, et al. (2003). Angiotensinogen gene M235T polymorphism and reduction in wall thickness in response to antihypertensive treatment. Clin Sci 105:637
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Boersma E, Simoons ML. (2010). Tailored therapy of ACE inhibitors in stable coronary artery disease: Pharmacogenetic profiling of treatment benefit. Pharmacogenomics 11:1115–1126
   PubMed Web of Science ®Google Scholar
• Candy S, Wright J, Gerber M, et al. (1995). A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37:674–678
   PubMed Web of Science ®Google Scholar
• Cao H, Hegele RA. (2002). DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet 47:620–622
   PubMed Web of Science ®Google Scholar
• Cappelen AW, Norheim OF, Tungodden B. (2008). Genomics and equal opportunity ethics. J Med Ethics 34:361–364
   PubMed Web of Science ®Google Scholar
• Carlini LE, Meropol NJ, Bever J. (2005). UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11:1226–1236
   PubMed Web of Science ®Google Scholar
• Carson PE, Flanagan CL, Ickes CE, Alving AS. (1956). Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124:484–485
   PubMed Web of Science ®Google Scholar
• Cheok MH, Lugthart S, Evans WE. (2006). Pharmacogenomics of acute leukemia. Annu Rev Pharmacol Toxicol 46:317–353
   PubMed Web of Science ®Google Scholar
• Chung CM, Wang RY, Chen JW, et al. (2010). A genome-wide association study identifies new loci for ACE activity: Potential implications for response to ACE inhibitor. Pharmacogenomics J 10:537–544
   PubMed Web of Science ®Google Scholar
• Cusi D, Barlassina C, Azzani T. (1997). Polymorphism of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 349:1353–1357
   PubMed Web of Science ®Google Scholar
• Dervieux T, Furst D, Lein DO, et al. (2004a). Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidy late synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50:2766–2774
   PubMed Web of Science ®Google Scholar
• Dervieux T, Greenstein N, Kremer J. (2006). Pharmacogenetic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 54:3095–3103
   PubMed Web of Science ®Google Scholar
• Dervieux T, Kremer J, Lein DO. (2004b). Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 14:733–739
   PubMedGoogle Scholar
• Dervieux T, Lein DO, Park G, et al. (2003). Single nucleotide polymorphisms (SNPs) in the folate/purine synthesis pathway predict methotrexate effect in rheumatoid arthritis. Arthritis Rheum 48:438
   Google Scholar
• Dewar JC, Wilkinson J, Wheatley A, et al. (1997). The glutamine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol 100:261–265
   PubMed Web of Science ®Google Scholar
• Diasio RB. (2001). Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology 15:21–26
   PubMedGoogle Scholar
• Dodge RR, Burrows B. (1980). The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis 122:567–575
   PubMed Web of Science ®Google Scholar
• Drazen M, Silverman EK, Lee TH. (2000). Heterogeneity of therapeutic responses in asthma. Br Med Bull 56:1054–1070
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687–1717
   PubMed Web of Science ®Google Scholar
• Evans WE. (2004). Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 26:186–191
   PubMed Web of Science ®Google Scholar
• Evans WE, Hon YY, Bomgaars L, et al. (2001). Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 19:2293–2301
   PubMed Web of Science ®Google Scholar
• Evans DAP, Manley KA, McKusick VA. (1956). Genetic control of isoniazid metabolism in man. Br Med J 2:485–491
   Google Scholar
• Evans WE, McLeod HL. (2003). Pharmacogenomics drug disposition, drug targets and side effects. N Engl J Med 348:538–549
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. (2004). Moving towards individualized medicine with pharmacogenomics. Nature 429:464–468
   PubMed Web of Science ®Google Scholar
• Farlow MR, Lahiri DK, Poirier J, et al. (1998). Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of subjects with Alzheimer's diseases. Neurology 50:669–677
   PubMed Web of Science ®Google Scholar
• Filigheddu F, Argiolas G, Degortes S, et al. (2010). Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension. Pharmacogenomics 11:319–325
   PubMed Web of Science ®Google Scholar
• Fisher MC, Cronstein BN. (2009). Meta-analysis of methylenetetrahydrofolatereductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 36:539–545
   PubMed Web of Science ®Google Scholar
• Fleming RA, Milano GA, Gaspard MH, et al. (1993). Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 29A:740–744
   PubMed Web of Science ®Google Scholar
• Fraser AG, Orchard TR, Jewell DP. (2002). The efficacy of azathioprine for the treatment of inflammatory bowel disease. Gut 50:485–489
   PubMed Web of Science ®Google Scholar
• Gadangi P, Longaker M, Naime D. (1996). The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 156:1937–1941
   PubMed Web of Science ®Google Scholar
• Gerdes LU, Gerdes C, Kervinen K. (2000). The apolipoprotein epsilon4 alleles determine sprognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian Simvastatin Survival Study. Circulation 101:1366–1371
   PubMed Web of Science ®Google Scholar
• Gerhard T, Gong Y, Beitelshees AL, et al. (2008). Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: Results from Genetic Substudy of the international Verapamil SR-trandolapril STudy (INVEST-GENES). Am Heart J 156:397–404
   PubMed Web of Science ®Google Scholar
• Goetz MP, Rae JM, Suman VJ. (2005). Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318
   PubMed Web of Science ®Google Scholar
• Goetz MP, Suman VJ, Ingle JN. (2006). A 2-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res 12:2080–2087
   PubMed Web of Science ®Google Scholar
• Hall IP, Wheatley A, Wilding P, Liggett SB. (1995). Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 345:1213–1214
   PubMed Web of Science ®Google Scholar
• Heggie GD, Sommadossi JP, Cross DS. (1987). Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203–2206
   PubMed Web of Science ®Google Scholar
• Hill EJ, Sharma RA. (2011). Multi-modality therapy of hepatic metastases from colorectal carcinoma: optimal combination of systemic chemotherapy with radio-embolization. J Nucl Med Radiat Ther 2:108
   Google Scholar
• Horie N, Aiba H, Oguro K, et al. (1995). Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 50-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20:191–197
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Goldberg RM, Qu P. (2007). UGT1A1*28 genotype and irinotecan induced neutropenia: Dose matters. J Natl Cancer Inst 99:1290–1295
   PubMed Web of Science ®Google Scholar
• Hoskins JM, Marcuello E, Altes A. (2008). Irinotecan pharmacogenetics: Influence of pharmacodynamic genes. Clin Cancer Res 14:1788–1796
   PubMed Web of Science ®Google Scholar
• Huang CC, Chung CM, Hung SI, et al. (2011). Genetic variation in renin predicts the effects of thiazide diuretics. Eur J Clin Invest 41:828–835
   PubMed Web of Science ®Google Scholar
• Hughes HB, Biehl JP, Jones AP, Schmidt LH. (1954). Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc 70:266–273
   PubMedGoogle Scholar
• Israel E, Chinchilli VM, Ford JG, et al. (2004). Use of regularly scheduled albuterol treatment in asthma: Genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364:1505–1512
   PubMed Web of Science ®Google Scholar
• Iyer L, Das S, Janisch L, et al. (2002). UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43–47
   PubMedGoogle Scholar
• Jin Y, Desta Z, Stearns V. (2005). CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39
   PubMed Web of Science ®Google Scholar
• Kalayci O, Birben E, Sackesen C, et al. (2006). ALOX5 promoter genotype, asthma severity and LTC production by eosinophils. Allergy 61:97–103
   PubMed Web of Science ®Google Scholar
• Kalow W. (1956). Familial incidence of low pseudocholinesterase level. Lancet 2:576
   Google Scholar
• Kalow W. (2006). Pharmacogenetics and pharmacogenomics: Origin, status, and the hope for personalized medicine. Pharmacogenomics J 6:162–165
   PubMed Web of Science ®Google Scholar
• Kawato Y, Aonuma M, Hirota Y, et al. (1991). Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT11. Cancer Res 51:4187–4191
   PubMed Web of Science ®Google Scholar
• Knapp MJ, Knopman DS, Solomon PR, et al. (1994). A week randomized controlled trial of high-dose tacrine in patients with Alzheimer's diseases. The Tacrine Study Group. J Am Med Assoc 271:985–991
   PubMed Web of Science ®Google Scholar
• Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. (1993). Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 88:1198–1205
   PubMed Web of Science ®Google Scholar
• Kotani Y, Nishimura Y, Maeda H, Yokoyama M. (1999). Beta2-adrenergic receptor polymorphisms affect airway responsiveness to salbutamol in asthmatics. J Asthma 36:583–590
   PubMed Web of Science ®Google Scholar
• Kumagai K, Hiyama K, Oyama T, et al. (2003). Polymorphisms in the thymidylate synthase and methylenetetrahydrofolatereductasa genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 11:593–600
   PubMed Web of Science ®Google Scholar
• Kumagai S, Komada F, Kita T. (2004). N-acetyltransferase 2 genotyperelated efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm Res 21:324–329
   PubMed Web of Science ®Google Scholar
• Ladero JM. (2008). Influence of polymorphic N-acetyltransferases on nonmalignant spontaneous disorders and on response to drugs. Curr Drug Metab 9:532–537
   PubMed Web of Science ®Google Scholar
• Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA. (1999). Azathioprine: An update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol Suppl 230:111–115
   PubMedGoogle Scholar
• Lazarou J, Pomeranz BH, Corey PN. (1998). Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. J Am Med Assoc 279:1200–1205
   PubMed Web of Science ®Google Scholar
• Lee DM, Weinblatt ME. (2001). Rheumatoid arthritis. Lancet 358:903–911
   PubMed Web of Science ®Google Scholar
• Leichman CG, Lenz HJ, Leichman L, et al. (1997). Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223–3229
   PubMed Web of Science ®Google Scholar
• Lennard L, Maddocks JL. (1983). Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells. J Pharm Pharmacol 135:15–18
   Google Scholar
• Liggett SB. (1997). Polymorphisms of the beta2-adrenergic receptor and asthma. Am J Respir Crit Care Med 156:156–162
   PubMed Web of Science ®Google Scholar
• Liggett SB. (2003). Polymorphisms of adrenergic receptors: Variations on a theme. Assay Drug Dev Technol 1:317–326
   PubMed Web of Science ®Google Scholar
• Lima JJ, Mohamed MH, Self TH, et al. (2000). Importance of beta (2) adrenergic receptor genotype, gender and race on albuterol-evoked bronchodilation in asthmatics. Pulm Pharmacol Ther 13:127–134
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Carlberg B, Samuelsson O. (2005). Should [beta] blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366:1545–1553
   PubMed Web of Science ®Google Scholar
• Liu X, Cheng D, Kuang Q, et al. (2014). Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: A meta-analysis in Caucasians. Pharmacogenomics J 14:120–129
   PubMed Web of Science ®Google Scholar
• Liu J, Liu ZQ, Yu BN, et al. (2006). Beta 1-adrenergic receptor polymorphisms influence the response to metoprololmonotherapy in patients with essential hypertension. Clin Pharm Therap 80:23–32
   PubMed Web of Science ®Google Scholar
• Lu Y, Qin X, Li S, et al. (2014) Quantitative assessment of CYP2D6 polymorphisms and risk of Alzheimer's disease: A meta-analysis. J Neurol Sci 343:15–22
   PubMed Web of Science ®Google Scholar
• Lu HF, Shih MC, Hsueh SC, et al. (2005). Molecular analysis of the thiopurine S-methyltransferase alleles in Bolivians and Tibetans. J Clin Pharm Ther 30:491–496
   PubMed Web of Science ®Google Scholar
• Luo F, Wang Y, Wang X, et al. (2009). A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. Hypertension 54:796–801
   PubMed Web of Science ®Google Scholar
• Lyss AP, Lilenbaum RC, Harris BE, Diasio RB. (1993). Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 11:239–240
   PubMed Web of Science ®Google Scholar
• Martin ER, Lai EH, Gilbert JR, et al. (2000). SNPing away at complex diseases: Analysis of single-nucleotide polymorphisms around APOE in Alzheimer's disease. Am J Hum Genet 67:383–394
   PubMed Web of Science ®Google Scholar
• Martinelli-Boneschi F, Giacalone G, Magnani G, et al. (2013). Pharmacogenomics in Alzheimer's disease: A genome-wide association study of response to cholinesterase inhibitors. Neurobiol Aging 34:1711
   PubMed Web of Science ®Google Scholar
• Martinez FD, Graves PE, Baldini M, et al. (1997). Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100:3184–3188
   PubMed Web of Science ®Google Scholar
• Massarweh S, Osborne C, Creighton C. (2008). Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68:826–833
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Cushman WC, et al. (1993). Single-drug therapy for hypertension in men – A comparison of six antihypertensive agents with placebo. N Engl J Med 328:914–921
   PubMed Web of Science ®Google Scholar
• Matheson MC, Ellis JA, Raven J, et al. (1995). Beta2-adrenergic receptor polymorphisms are associated with asthma and COPD in adults. J Hum Genet 51:943–951
   Web of Science ®Google Scholar
• McLeod HL, Krynetski EY, Relling MV, Evans WE. (2000). Genetic polymorphism of thiopurinemethyltransferase and its clinical relevance for childhood acute lymphoblastic leukaemia. Leukaemia 14:567–572
   PubMed Web of Science ®Google Scholar
• Meyer JE, Cohen SJ. (2011). Beyond first-line therapy: Combining chemotherapy and radioembolization for hepatic colorectal metastases. J Nucl Med Radiat Ther 2:103
   Google Scholar
• Nielsen OH, Vainer B, Rask-Madsen J. (2001). Review article: The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 15:1699–1708
   PubMed Web of Science ®Google Scholar
• Nishimura R, Nagaom K, Miyayama H, et al. (1999). Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res 19:5621–5626
   PubMed Web of Science ®Google Scholar
• Nitsch RM, Blustajin JK, Pittas AG, et al. (1992). Evidences for membrane defect in Alzheimer's diseases. Proc Natl Acad Sci USA 89:1671–1675
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Kontula K, Benn M, et al. (2010). Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study. Pharmacogenet Genom 20:77–85
   PubMed Web of Science ®Google Scholar
• Ordovas JM, Lopez-Miranda J, Perez-Jimenez F. (1995). Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113:157–166
   PubMed Web of Science ®Google Scholar
• Padhukasahasram B, Yang JJ, Levin AM, et al. (2014). Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups. Pharmacogenomics J 14:365–371
   PubMed Web of Science ®Google Scholar
• Park HW, Tantisira KG, Weiss ST. (2015). Pharmacogenomics in asthma therapy: Where are we and where do we go. Annu Rev Pharmacol Toxicol 55:129–147
   PubMed Web of Science ®Google Scholar
• Pawlik A, Herczynska M, Kurzawski M, et al. (2009). The effect of exon (19C-A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 10:303–309
   PubMed Web of Science ®Google Scholar
• Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B. (2004). The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42:496–503
   PubMed Web of Science ®Google Scholar
• Pignatti PF. (2004). Trends in pharmacogenomics of drugs used in the treatment of asthma. Pharmacol Res 49:343–349
   PubMed Web of Science ®Google Scholar
• Poirier J. (1999). Apolipoprotein E4 cholinergic integrity and the pharmacogentics of Alzheimer's disease. J Psychiatry Neurosci 24:147–153
   PubMed Web of Science ®Google Scholar
• Poirier J, Delisle MC, Quirion R, et al. (1995). Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 92:12260–12264
   PubMed Web of Science ®Google Scholar
• Present DH, Meltzer SJ, Krumholz MP, et al. (1989). 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity. Ann Intern Med 111:641–649
   PubMed Web of Science ®Google Scholar
• Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. (2001). Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65–70
   PubMedGoogle Scholar
• Raida M, Schwabe W, Hausler P, et al. (2001). Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7:2832–2839
   PubMed Web of Science ®Google Scholar
• Ranganathan P, McLeod HL. (2006). Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 54:1366–1377
   PubMed Web of Science ®Google Scholar
• Redon J, Luque-Otero M, Martell N, Chaves FJ. (2004). Renin–angiotensin system gene polymorphisms: Relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Pharmacogenomics J 5:14–20
   Web of Science ®Google Scholar
• Rego PI, Fernández MM, Carreira GV, Blanco FJ. (2009). Gene polymorphisms and pharmacogenetics in rheumatoid arthritis. Reumatol Clin 5:268–279
   Google Scholar
• Relling MV, Hancock ML, Rivera GK, et al. (1999). Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001–2008
   PubMed Web of Science ®Google Scholar
• Richard F, Helbecque N, Neuman E, et al. (1997). APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet 349:539
   PubMed Web of Science ®Google Scholar
• Rosskopf D, Michel MC. (2008). Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine. Pharmacol Rev 60:513–535
   PubMed Web of Science ®Google Scholar
• Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. (2000). Enhanced expression of the leukotriene C (4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 23:290–296
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. (2001). Rational dosing of azathioprine and 6-mercaptopurine. Gut 48:591
   PubMed Web of Science ®Google Scholar
• Schneider LS, Farlow MR. (1995). Predicting response to cholinesterase inhibitors in Alzheimer's disease. Possible approaches. CNS Drugs 4:114–124
   Web of Science ®Google Scholar
• Schwab M, Schäffeler E, Marx C. (2002). Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: Impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12:429–436
   PubMedGoogle Scholar
• Schwab M, Zanger U, Marx C. (2008). Role of genetic and nongenetic factors for fluorouracil treatment- related severe toxicity: A prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26:2131–2138
   PubMed Web of Science ®Google Scholar
• Sciarrone MT, Stella P, Barlassina C, et al. (2003). ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 41:398–403
   PubMed Web of Science ®Google Scholar
• Sehrt D, Meineke I, Tzvetkov M, et al. (2011). Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics. Pharmacogenomics 12:783–795
   PubMed Web of Science ®Google Scholar
• Siest G, Bertrand P, Herbeth B. (2000). Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses. Clin Chem Lab Med 38:841–852
   PubMed Web of Science ®Google Scholar
• Singh NK, Banerjee BD, Bala K, et al. (2014). Polymorphism in cytochrome P450 2D6, glutathione S-transferases Pi 1 genes, and organochlorine pesticides in Alzheimer disease: A case-control study in North Indian population. J Geriatr Psychiatry Neurol 27:119–127
   PubMed Web of Science ®Google Scholar
• Stephen T, Turner Gary L, Schwartz Arlene B, Chapman Eric Boerwinkle WN. (2005). K1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 46:758–765
   PubMed Web of Science ®Google Scholar
• Stipp DA. (2000). DNA tragedy. Fortune 142:170–178
   PubMed Web of Science ®Google Scholar
• Stocco G, Cheok MH, Crews KR, et al. (2009). Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 85:164–172
   PubMed Web of Science ®Google Scholar
• Su X, Lee L, Li X, et al. (2007). Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to anangiotensin-converting enzyme inhibitor. Circulation 115:725–732
   PubMed Web of Science ®Google Scholar
• Svensson-Färbom P, Wahlstrand B, Almgren P, et al. (2011). A functional variant of the NEDD4L gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients. J Hypertens 29:388–395
   PubMed Web of Science ®Google Scholar
• Tan S, Hall IP, Dewar J, et al. (1997). Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe stable asthmatics. Lancet 350:995–999
   PubMed Web of Science ®Google Scholar
• Taniguchi A, Urano W, Tanaka E. (2007). Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 17:383–390
   PubMed Web of Science ®Google Scholar
• Toffoli G, Cecchin E, Corona G. (2006). The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061–3068
   PubMed Web of Science ®Google Scholar
• Turner ST, Bailey KR, Fridley BL, et al. (2008). Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 52:359–365
   PubMed Web of Science ®Google Scholar
• Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. (2001). C825T polymorphism of the G protein β3-subunit and antihypertensive response to a thiazide diuretic. Hypertension 37:739
   PubMed Web of Science ®Google Scholar
• Ulrich CM, Bigler J, Velicer CM, et al. (2000). Searching expressed sequence tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 9:1381–1385
   PubMed Web of Science ®Google Scholar
• Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. (2002). High prevalence of the IVS14 1G → A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12:555–558
   PubMedGoogle Scholar
• Van Triest B, Pinedo HM, van Hensbergen Y, et al. (1999). Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 5:643–654
   PubMed Web of Science ®Google Scholar
• Visser K, Katchamart W, Loza E. (2009). Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum 68:1086–1093
   PubMed Web of Science ®Google Scholar
• Wall AM, Rubnitz JE. (2003). Pharmacogenomic effects on therapy for acute lymphoblastic leukemia in children. Pharmacogenomics J 3:128–135
   PubMed Web of Science ®Google Scholar
• Wang DG, Fan JB, Siao CJ, et al. (1998). Large scale identification, mapping, and genotyping of SNP in the human genome. Science 280:1077–1082
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Lehman E, Lazarus SC, et al. (2004). Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 173:519–526
   Web of Science ®Google Scholar
• Weinshilboum RM, Sladek SL. (1980). Mercaptopurinepharmacogenetics: Monogenic inheritance of erythrocyte thiopurinemethyltransferase activity. Am J Hum Genet 32:651–662
   PubMed Web of Science ®Google Scholar
• Weinshilboum R, Wang L. (2004). Inheritance and drug response. N Engl J Med 348:529–537
   Web of Science ®Google Scholar
• Werner D, Werner U, Meybaum A, et al. (2008). Determinants of steady-state torasemide pharmacokinetics: Impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. Clin Pharmacokinet 47, 323–332
   PubMed Web of Science ®Google Scholar
• Wright Jr JT, Probstfield JL, Cushman WC, et al. (2009). ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 169:832–842
   PubMed Web of Science ®Google Scholar
• Yu H, Lin S, Jin L, et al. (2009). Adenine/cytosine1166polymorphism of the angiotensin II type 1 receptor gene and the antihypertensive response to angiotensin-converting enzyme inhibitors. J Hypertens 27:2278
   PubMed Web of Science ®Google Scholar